Gastroenteric tumor
Conditions
Interventions
RS group:In the RS group, under the premise of 0.1ug/kg sufentanil analgesia, the dose of remazolam 10mg/kg/h was continuously pumped until the BIS value dropped to 40-60. Remazolam was continuously p
PS group:Under the premise of the same dose of sufentanil for analgesia, the PS group was continuously injected with propofol at a speed of 100mg/kg/h until the BIS value decreased to 40-60. Propofol
PS group:In the PA group, the equivalent dose of sufentanil (7ug/kg) was injected with propofol at a rate of 100mg/kg/h until the BIS value decreased to 40-60. Propofol was injected at a rate of 4-10m
RA group:After intravenous infusion of afentanil (7ug/kg) in RA group, ramazolam was pumped at a dose of 10mg/kg/h until BIS value dropped to 40-60. Remazolam was continuously pumped at a rate of 1-2m
Sponsors
Macheng People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Age 18~65 years old, gender is not limited; (2) Those who are diagnosed with submucosal tumors after routine gastric and colonoscopy and plan to undergo elective submucosal tumor resection; (3) American Society of Anesthesiologists ASA grade I.-III; (4) BMI 18.5-30kg/m^2; (5) Informed consent, voluntarily participate in the trial, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Subject clearly refuses to participate in this study; (2) Those with a history of severe heart, brain, lung, liver, kidney diseases and metabolic diseases; (3) Those with obvious contraindications to surgery; (4) Patients with acute inflammation of the respiratory tract within 2 weeks; (5) Systolic blood pressure > 180mmHg and/or diastolic blood pressure >110mmHg in patients with preoperative hypertension, or 90/60mmHg < patients with hypotension; (6) Those who are allergic to the drugs that may be used in the study; (7) Those with neuromuscular system diseases and mental diseases; (8) Those who are suspected of abusing narcotic analgesics or sedatives; (9) Those who predict that difficult airway may occur or have occurred; (10) Subjects who are considered inappropriate by the investigator to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of anesthesia-related adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Success rate of anesthesia;Patient and surgeon satisfaction;Postoperative quality of life score; | — |
Countries
China
Contacts
Public ContactJiang Peiyan
Macheng People's Hospital
Outcome results
None listed